questionId
int32 337
40.1k
| question
stringlengths 11
168
| question_types
listlengths 1
4
| image
imagewidth (px) 200
7.07k
| docId
int32 279
12.9k
| ucsf_document_id
stringlengths 8
8
| ucsf_document_page_no
stringclasses 160
values | answers
listlengths 1
14
|
---|---|---|---|---|---|---|---|
956 | From whom has this email been sent? | [
"layout"
] | 465 | xtjf0226 | 1 | [
"Kanayama Kiyoshi"
] |
|
957 | Who are on the CC list? | [
"form",
"layout"
] | 465 | xtjf0226 | 1 | [
"Shephard, Kirk (TPI); Fuse, Touichirou (TPC)"
] |
|
958 | What is the email ID of Kanayama Kiyoshi? | [
"layout"
] | 465 | xtjf0226 | 1 | [
"Kanayama_Kiyoshi@takeda.co.jp"
] |
|
959 | What is the subject of this email? | [
"layout"
] | 465 | xtjf0226 | 1 | [
"Re: Potential Publicaton in Correspondence Section of The Lancet"
] |
|
960 | What is the level of importance of the email send by Witte, Kimberly? | [
"form"
] | 463 | tsjf0226 | 1 | [
"High"
] |
|
961 | What is the subject of the document? | [
"form"
] | 463 | tsjf0226 | 1 | [
"fw: skb problems",
"FW: SKB PROBLEMS"
] |
|
962 | What is the EXHIBIT number mentioned? | [
"form"
] | 463 | tsjf0226 | 1 | [
"9"
] |
|
963 | What is the exhibit no given in the document? | [
"form",
"layout"
] | 463 | tsjf0226 | 1 | [
"9"
] |
|
964 | Who is this Memo to? | [
"form"
] | 476 | sqjf0226 | 2 | [
"distribution",
"Distribution"
] |
|
965 | What is the date mentioned? | [
"layout"
] | 476 | sqjf0226 | 2 | [
"JULY 19, 2002",
"July 19, 2002"
] |
|
966 | Whose signature is present at the bottom? | [
"layout"
] | 476 | sqjf0226 | 2 | [
"MARLENE C. DUBAS",
"Marlene C. Dubas"
] |
|
971 | who are in the cc? | [
"form"
] | 461 | tzjf0226 | 1 | [
"johnston,Kendra; precurato-grubb, marti"
] |
|
972 | Who is the 23rd Addressee mentioned in the list? | [
"table/list",
"layout"
] | 470 | srjf0226 | 17 | [
"Senior Vice President, Accounting Center"
] |
|
973 | Heading of the document? | [
"layout"
] | 471 | xsjf0226 | 3 | [
"Draft Agenda",
"Draft Agenda?"
] |
|
975 | What are the timings for Continental Breakfast? | [
"table/list"
] | 471 | xsjf0226 | 3 | [
"8:00-9:00"
] |
|
976 | what is the "subject" of this letter? | [
"form"
] | 461 | tzjf0226 | 1 | [
"article in today's USA Today regarding Avandia hearing"
] |
|
978 | who is writing this letter? | [
"form",
"layout"
] | 461 | tzjf0226 | 1 | [
"CHEN, GIGI",
"chen, gigi",
"gigi m. chen, MBA"
] |
|
979 | when was this letter sent? | [
"form"
] | 461 | tzjf0226 | 1 | [
"7/31/2007 11:48:09 AM",
"7/31/2007 11:48:09 am"
] |
|
980 | who is the premier sales representative ? | [
"layout"
] | 461 | tzjf0226 | 1 | [
"gigi m. chen, MBA",
"gigi m.chen"
] |
|
981 | what is the title of this page? | [
"others",
"layout"
] | 480 | xsjf0226 | 6 | [
"Executive Summary, cont.",
"executive summary, cont."
] |
|
982 | Heading of the document? | [
"layout"
] | 481 | xsjf0226 | 4 | [
"response document",
"Response Document"
] |
|
983 | what is the first point under the title-executive summary, cont. | [
"table/list"
] | 480 | xsjf0226 | 6 | [
"Proposed experiments",
"proposed experiments"
] |
|
987 | What is the full form of FDA? | [
"layout"
] | 484 | hsjf0226 | 1 | [
"Food and Drug Administration"
] |
|
989 | What is the date mentioned? | [
"form"
] | 484 | hsjf0226 | 1 | [
"January 3, 2003"
] |
|
990 | who is writing this letter? | [
"form"
] | 483 | sqjf0226 | 1 | [
"Marlene Dubas",
"marlene dubas"
] |
|
992 | who is in the cc? | [
"form"
] | 483 | sqjf0226 | 1 | [
"Tom Muldoon",
"tom muldoon"
] |
|
993 | Who is the sender of this fax? | [
"form"
] | 484 | hsjf0226 | 1 | [
"Jena Weber"
] |
|
994 | What is the total no of pages in the fax including cover? | [
"layout"
] | 484 | hsjf0226 | 1 | [
"1"
] |
|
998 | Which all compaies are added as defendants in a lawsuit? | [
"free_text"
] | 483 | sqjf0226 | 1 | [
"Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals America, Inc."
] |
|
1,001 | what is 'RE' in the letter? | [
"form"
] | 483 | sqjf0226 | 1 | [
"Preservation of Documents and Electronic Data relating to Actos",
"preservation of documents and electronic data relating to actos"
] |
|
1,002 | Heading of the first paragraph? | [
"layout"
] | 487 | lzjf0226 | 4 | [
"SIXTH OBJECTION"
] |
|
1,003 | Name of the judge? | [
"free_text"
] | 487 | lzjf0226 | 4 | [
"Patrick Hanna"
] |
|
1,004 | What is the page no mentioned in this document? | [
"free_text",
"layout"
] | 487 | lzjf0226 | 4 | [
"3"
] |
|
1,005 | When was the hearing before Judge? | [
"free_text"
] | 487 | lzjf0226 | 4 | [
"July 25, 2013"
] |
|
1,037 | What is the date mentioned? | [
"layout"
] | 501 | ttjf0226 | 5 | [
"January 14, 1999"
] |
|
1,040 | What is the name of the company mentioned in the letterhead? | [
"layout"
] | 503 | kmjf0226 | 1 | [
"DEPARTMENT OF HEALTH & HUMAN SERVICES"
] |
|
1,041 | What is the company name ? | [
"layout"
] | 501 | ttjf0226 | 5 | [
"ELI LILLY AND COMPANY"
] |
|
1,042 | What is the fullform of NDA? | [
"free_text"
] | 503 | kmjf0226 | 1 | [
"new drug application",
"New drug application."
] |
|
1,043 | What is the date mentioned? | [
"layout"
] | 502 | gnjf0226 | 1 | [
"August 16, 1999"
] |
|
1,044 | What is the name of the addressee? | [
"layout"
] | 503 | kmjf0226 | 1 | [
"Ms. Pritza",
"Mary Jo Pritza, MPH, PharmD"
] |
|
1,045 | To whom is this letter addressed? | [
"layout"
] | 502 | gnjf0226 | 1 | [
"Alan D. Mackenzie",
"Alan"
] |
|
1,046 | What is the full form of TPA? | [
"free_text"
] | 502 | gnjf0226 | 1 | [
"Takeda Pharmaceuticals America, Inc.",
"Takeda Pharmaceuticals America Inc.",
"Takeda Pharmaceuticals America"
] |
|
1,047 | What kind of a letter is this ? | [
"layout"
] | 503 | kmjf0226 | 1 | [
"DISCIPLINE REVIEW LETTER"
] |
|
1,048 | Which two companies have agreed to amend the Co-Promotion Agreement? | [
"free_text"
] | 502 | gnjf0226 | 1 | [
"Takeda Pharmaceuticals America, Inc. (\"TPA\") and Eli Lilly and Company (\"Lilly\")"
] |
|
1,049 | What is the name of the company? | [
"layout"
] | 504 | lljf0226 | 1 | [
"THE UPJOHN COMPANY"
] |
|
1,051 | What is the date mentioned? | [
"layout"
] | 504 | lljf0226 | 1 | [
"September 21, 1993"
] |
|
1,052 | To whom is this letter addressed? | [
"layout"
] | 504 | lljf0226 | 1 | [
"Doctor Matsuzawa",
"Tai Matsuzawa, Ph.D.",
"Tai Matsuzawa, Ph.D",
"Matsuzawa"
] |
|
1,053 | As a consequence of the decision Upjohn must decline participation with which company? | [
"free_text"
] | 504 | lljf0226 | 1 | [
"Takeda"
] |
|
1,055 | A 79-year-old female was enrolled in the study for how many days? | [
"free_text"
] | 507 | gyjf0226 | 2 | [
"200 days"
] |
|
1,056 | The patient had a history of bladder cancer since when? | [
"free_text"
] | 507 | gyjf0226 | 2 | [
"1996",
"since 1996"
] |
|
1,057 | Who is the general manager of International development Dept. of Takeda Chemical Industires, Ltd.? | [
"others",
"layout"
] | 509 | mljf0226 | 2 | [
"K. Kitazawa, Ph. D."
] |
|
1,058 | Who is the writer of the document? | [
"layout"
] | 507 | gyjf0226 | 2 | [
"Janet L. Haskins"
] |
|
1,059 | The woman had a positive history of what? | [
"free_text"
] | 507 | gyjf0226 | 2 | [
"tobacco use"
] |
|
1,061 | what is the name of the industry ? | [
"layout"
] | 509 | mljf0226 | 2 | [
"TAKEDA CHEMICAL INDUSTRIES, LTD.",
"TAKEDA CHEMICAL INDUSTRIES , LTD ."
] |
|
1,063 | How many pages are there in total? | [
"layout"
] | 509 | mljf0226 | 2 | [
"2",
"Page 2 of 2"
] |
|
1,065 | what is the month and date mentioned in this letter, at the top ? | [
"layout"
] | 509 | mljf0226 | 2 | [
"October 25",
"october 25"
] |
|
1,066 | By whom is this document written? | [
"table/list",
"layout"
] | 511 | ksjf0226 | 4 | [
"Stacey Dixon Calahan"
] |
|
1,068 | What is the date mentioned? | [
"form",
"layout"
] | 514 | nljf0226 | 1 | [
"January 21, 1999"
] |
|
1,069 | To whom is this document addressed? | [
"form",
"layout"
] | 514 | nljf0226 | 1 | [
"Mr. Larry Ellingson",
"Mr. Ellingson"
] |
|
1,070 | to which department it belongs to ? | [
"free_text",
"layout"
] | 513 | gyjf0226 | 3 | [
"DEPARTMENT OF HEALTH AND HUMAN SERVICES",
"department of health and human services."
] |
|
1,071 | By whom is this document written? | [
"form",
"layout"
] | 514 | nljf0226 | 1 | [
"Kunio Iwatani"
] |
|
1,073 | what is the date of submission? | [
"form",
"layout"
] | 513 | gyjf0226 | 3 | [
"11/18/2002"
] |
|
1,074 | what is the telephone number (include area code)? | [
"form",
"layout"
] | 513 | gyjf0226 | 3 | [
"847-383-3739"
] |
|
1,076 | What is the serial number mentioned in the form? | [
"form",
"layout"
] | 513 | gyjf0226 | 3 | [
"5 0 1"
] |
|
1,077 | what is the expiration date ? | [
"form",
"layout"
] | 513 | gyjf0226 | 3 | [
"November 30, 2002",
"november 30, 2002"
] |
|
1,078 | what is the name of the sponsor ? | [
"form",
"layout"
] | 513 | gyjf0226 | 3 | [
"Takeda Pharmaceuticals North America, Inc.",
"Takeda Pharmaceuticals North america , Inc."
] |
|
1,079 | what has to be investigated before starting pioglitazone therapy? | [
"free_text",
"layout"
] | 515 | psjf0226 | 5 | [
"any macroscopic haematuria"
] |
|
1,080 | what has been experienced commonly in patients taking actos in combination with insulin? | [
"free_text",
"layout"
] | 515 | psjf0226 | 5 | [
"Heart failure",
"heart failure"
] |
|
1,081 | Which foundation is mentioned in this document? | [
"others",
"layout"
] | 517 | zfkf0226 | 2 | [
"Cleveland Clinic Foundation",
"The Cleveland Clinic Foundation"
] |
|
1,082 | Under which department , The Cleveland Clinic Foundation operates? | [
"others",
"layout"
] | 517 | zfkf0226 | 2 | [
"Department of Cardiovascular Medicine",
"Department of Cardiovascular Medicine."
] |
|
1,083 | What is written in big bold letters at the bottom? | [
"layout"
] | 514 | nljf0226 | 1 | [
"DALY 19"
] |
|
1,084 | Which medicine is used to treat type 2 diabetes mellitus? | [
"free_text",
"layout"
] | 515 | psjf0226 | 5 | [
"Actos/Competact"
] |
|
1,087 | How many cases of bladder cancer from 12506 patients were reported? | [
"free_text",
"layout"
] | 515 | psjf0226 | 5 | [
"19 cases"
] |
|
1,088 | What is the PO Box number? | [
"free_text"
] | 517 | zfkf0226 | 2 | [
"931535"
] |
|
1,090 | what is the IND mumber (if previously assigned ) ? | [
"form",
"layout"
] | 518 | tyjf0226 | 3 | [
"33,729"
] |
|
1,091 | What is the serial number mentioned in the form? | [
"form",
"layout"
] | 518 | tyjf0226 | 3 | [
"4 9 7"
] |
|
1,092 | what is the date of submission ? | [
"form",
"layout"
] | 518 | tyjf0226 | 3 | [
"11/1/02"
] |
|
1,093 | what is the Name(s) of drug (include all available names: Trade , Generic, Chemical, Code)? | [
"form",
"layout"
] | 518 | tyjf0226 | 3 | [
"ACTOS (pioglitazone HCI)",
"ACTOS (Pioglitazone HCI)"
] |
|
1,094 | What is the Tax ID mentioned in this document? | [
"form"
] | 517 | zfkf0226 | 2 | [
"34-0714585"
] |
|
1,096 | what is the form approved : OMB No | [
"form",
"layout"
] | 518 | tyjf0226 | 3 | [
"0910-0014",
"0910-0014."
] |
|
1,097 | What is the word written in bold on the top of the document? | [
"layout"
] | 505 | psjf0226 | 1 | [
"Takeda"
] |
|
1,098 | What is the date mentioned? | [
"layout"
] | 505 | psjf0226 | 1 | [
"19th January 2012"
] |
|
1,099 | what is the name of pharmaceuticals ? | [
"free_text",
"layout"
] | 519 | xyjf0226 | 1 | [
"Takeda Pharmaceuticals North America, Inc.",
"TAkeda pharmaceuticals North America ,INc."
] |
|
1,101 | to whom this letter is written ? | [
"form",
"layout"
] | 519 | xyjf0226 | 1 | [
"Janet L. Haskins",
"janet L. haskins",
"Ms. Haskins"
] |
|
1,102 | When did Regulatory affairs department receive this letter? | [
"Image/Photo",
"layout"
] | 519 | xyjf0226 | 1 | [
"JUN 16 2003"
] |
|
1,105 | To whom was this letter written? | [
"layout"
] | 505 | psjf0226 | 1 | [
"Healthcare Professional"
] |
|
1,107 | What is the fifth point? | [
"table/list",
"layout"
] | 510 | frjf0226 | 3 | [
"WAC and AWP generally;",
"WAC AND AWP generally;"
] |
|
1,108 | Education grants regarding which products? | [
"table/list",
"free_text"
] | 510 | frjf0226 | 3 | [
"TPNA",
"TPNA products"
] |
|
1,109 | What is the date this document was last printed? | [
"layout"
] | 510 | frjf0226 | 3 | [
"11/30/2012",
"11/30/2012 4:28:00 AM"
] |
|
1,110 | To whom a copy of cover letter has to be sent ? | [
"free_text",
"layout"
] | 519 | xyjf0226 | 1 | [
"Ms. Jens Weber"
] |
|
1,111 | Which reimbursement for TPNA pharmaceutical products is generally given? | [
"table/list",
"free_text"
] | 510 | frjf0226 | 3 | [
"Medicare and Medicaid"
] |
|
1,113 | What is the designation of Alfonso T. Perez, M.D.? | [
"layout"
] | 512 | zfkf0226 | 5 | [
"Vice President, Clinical Research"
] |
|
1,114 | By whom was this agreement Agreed and Accepted? | [
"form",
"layout"
] | 512 | zfkf0226 | 5 | [
"Richard A. Rudick, M.D.",
"Richard A. Rudick",
"Richard A. Rudick, M.D. Chairman, Division of Clinical Research"
] |
|
1,115 | What is the full form of FAR? | [
"table/list",
"free_text",
"layout"
] | 512 | zfkf0226 | 5 | [
"Federal Acquisitions Regulation"
] |
|
1,116 | What is the number written above TAK-INDNDA-01577086? | [
"layout"
] | 520 | xyjf0226 | 2 | [
"425"
] |
|
1,117 | What is the contact number of Ms. Jena Weber, Regulatory Project Manager? | [
"free_text"
] | 520 | xyjf0226 | 2 | [
"301-827-6422"
] |
|
1,118 | What is the full form of ODE? | [
"free_text"
] | 520 | xyjf0226 | 2 | [
"Office of Drug Evaluation"
] |
|
1,119 | What is written above Page 2 on the top? | [
"layout"
] | 520 | xyjf0226 | 2 | [
"IND 33, 729"
] |
|
1,120 | what is the unit mentioned in the letter ? | [
"form"
] | 521 | zsjf0226 | 1 | [
"7200"
] |
|
1,121 | what is the date mentioned | [
"handwritten",
"form"
] | 521 | zsjf0226 | 1 | [
"9/23/93"
] |